Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Cancer Imaging and Image-directed Interventions

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1642253

This article is part of the Research TopicThe Emerging Role of Biomarker Mutations in Early Stage Non-small Cell Lung Cancer (NSCLC) ManagementView all articles

Noninvasive Prediction of EGFR 19Del and 21L858R Subtypes in Lung Adenocarcinoma: A Comparative Study of Logistic Regression and Decision Tree Models

Provisionally accepted
Peng  HanPeng HanDai  ZhangDai ZhangWenjun  YaoWenjun YaoMengYu  LvMengYu LvYunHong  QianYunHong QianHong  ZhaoHong Zhao*
  • Second Hospital of Anhui Medical University, Hefei, China

The final, formatted version of the article will be published soon.

Objective: Despite the increasing interest in radiogenomic prediction, few studies have directly compared the performance of logistic regression and decision tree models in distinguishing epidermal growth factor receptor (EGFR) mutation subtypes. This study provides the first systematic comparison of the predictive performance of these two models in identifying exon 19 deletions (19Del) and exon 21 L858R point mutations (21L858R) in patients with lung adenocarcinoma. By leveraging imaging and clinical parameters, we aimed to address a critical gap in the literature by establishing an optimal prediction model and providing a noninvasive tool to support personalized treatment strategies for patients with unknown EGFR mutation status. Materials and Methods: We retrospectively collected clinical and radiological data from 193 patients with histologically confirmed lung adenocarcinoma who were admitted to the Second Affiliated Hospital of Anhui Medical University between May 2018 and June 2024. Based on EGFR genotyping results, patients were stratified into two groups: the EGFR 19Del mutation group and the EGFR 21L858R mutation group. including Student's t-test, Mann–Whitney U test, chi-square test, or Fisher's exact test—were performed to evaluate differences in clinical and CT imaging characteristics between groups. Variables with P < 0.05 in the univariate analysis were subsequently included in both logistic regression and decision tree models to identify independent predictors of EGFR mutation subtype. Model performance was assessed using ROC curve analysis. The area under the curve (AUC) was calculated for each model, and their predictive accuracy was further compared using DeLong's test, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Results: In the decision tree model, age and brain metastasis emerged as key decision nodes for differentiating 19Del and 21L858R mutations, with an AUC of 0.712 (95% CI: 0.639–0.785). In contrast, the logistic regression model identified age, pleural 2 thickening, lymphadenopathy, and brain metastasis as independent predictors, achieving a higher AUC of 0.740 (95% CI: 0.671–0.810). The NRI and IDI values were 0.498 (P < 0.001, 95% CI: 0.238–0.758) and 0.043 (P = 0.004, 95% CI: 0.013–0.072), respectively, DeLong's test revealed no statistically significant difference between the AUCs of the two models (Z = 1.314, P = 0.189).

Keywords: EGFR, Lung Adenocarcinoma, Decision tree model, logistic regression model, NRI

Received: 06 Jun 2025; Accepted: 29 Aug 2025.

Copyright: © 2025 Han, Zhang, Yao, Lv, Qian and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Hong Zhao, Second Hospital of Anhui Medical University, Hefei, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.